<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03865134</url>
  </required_header>
  <id_info>
    <org_study_id>10840098-604.01.01-E.34158</org_study_id>
    <nct_id>NCT03865134</nct_id>
  </id_info>
  <brief_title>Evaluation of Visual - Motor Development in Children With Retinopathy of Prematurity</brief_title>
  <official_title>Evaluation of Visual - Motor Integration and Motor Coordination in Children With Retinopathy of Prematurity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istanbul Medipol University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istanbul Medipol University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study was to investigate the eye structure, visual impairment, visual motor
      development and motor coordination of children between 2-6 ages that had applied to diod
      laser photocoagulation and intravitreal anti - vascular endothelial growth factor treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There are three different groups in this study. Children between 2-6 ages that had applied to
      diod laser photocoagulation and intravitreal anti - vascular endothelial growth factor
      treatment will have evaluated with Snellen Test, Titmus Fly Test, Optical Kohlerans
      Tomography, Beery-Buktenica Developmental Test of Visual Motor Integration, Peabody
      Developmental Motor Scales-II, World Health Organization Quality of Life - BREF and State -
      Trait Anxiety Inventory.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 20, 2018</start_date>
  <completion_date type="Actual">April 25, 2019</completion_date>
  <primary_completion_date type="Actual">March 25, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Motor Integration</measure>
    <time_frame>3 weeks</time_frame>
    <description>Visual-motor integration (VMI) is &quot;the degree to which visual perception and finger-hand movements are well coordinated&quot; and will asses with Beery-Buktenica Developmental Test of Visual-Motor Integration in this study. This test is a standardized, norm-referenced assessment involving copying geometric forms that is used to determine the level of integration between visual and motor systems in people of all ages.
The Short Format and Full Format tests take about 10-15 minutes each to administer. Results are reported as standard scores, percentiles, and age equivalents.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Perception</measure>
    <time_frame>3 weeks</time_frame>
    <description>Visual perception will asses with Beery-Buktenica Developmental Test of Visual-Motor Integration in this study. This test is a standardized, norm-referenced assessment involving copying geometric forms that is used to determine the level of integration between visual and motor systems in people of all ages. Visual Perception test takes about 5 minutes. Results are reported as standard scores, percentiles, and age equivalents.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Motor Coordination</measure>
    <time_frame>3 weeks</time_frame>
    <description>Motor Coordination is coordination of finger movements and will asses by Beery-Buktenica Developmental Test of Visual-Motor Integration in this study. This test is a standardized, norm-referenced assessment involving copying geometric forms that is used to determine the level of integration between visual and motor systems in people of all ages. Motor coordination test takes about 5 minutes. Results are reported as standard scores, percentiles, and age equivalents.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Retinal Layers' Development</measure>
    <time_frame>3 weeks</time_frame>
    <description>Development of retinal layers will assess with Optical coherence tomography (OCT). The OCT allows for in vivo, cross-sectional assessment of eye tissue, including the retina and its vasculature. By comparing the interference patterns of light that passes through live tissue to a reference arm, OCT provides high-resolution imaging of just a few microns of eye microanatomy.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Quality of Life in Parents</measure>
    <time_frame>3 weeks</time_frame>
    <description>Quality of life assessment of parents will evaluate with The WHOQOL-BREF instrument that is comprises 26 items, which measure the following broad domains: physical health, psychological health, social relationships, and environment.</description>
  </other_outcome>
  <other_outcome>
    <measure>State - Trait Anxiety of Parents</measure>
    <time_frame>3 weeks</time_frame>
    <description>State and trait anxiety level of parents will asses by the State-Trait Anxiety Inventory (STAI) that is a commonly used measure of trait and state anxiety. It can be used in clinical settings to diagnose anxiety and to distinguish it from depressive syndromes. It also is often used in research as an indicator of caregiver distress.The STAI has 20 items for assessing trait anxiety and 20 for state anxiety.</description>
  </other_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">69</enrollment>
  <condition>Premature Retinopathy</condition>
  <condition>Visual Impairment</condition>
  <condition>Motor Delay</condition>
  <arm_group>
    <arm_group_label>Laser Group</arm_group_label>
    <description>Children with premature retinopathy treated with Laser therapy. All cases are evaluated with Snellen Test, Autorefractometer, Titmus Stereo Fly Test, Optical Kohlerans Tomography, Peabody Developmental Motor Scales - II. Investigation of Visual Motor Integration will evaluate with Beery- Buktenica Developmental Test of Visual Motor Integration and Peabody. Parents are evaluated World Health Organization Quality of Life - BREF and State - Trait Anxiety Inventory.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anti-VEGF Group</arm_group_label>
    <description>Children with premature retinopathy treated with anti-VEGF therapy. All cases are evaluated with Snellen Test, Autorefractometer, Titmus Stereo Fly Test, Optical Kohlerans Tomography, Peabody Developmental Motor Scales - II. Investigation of Visual Motor Integration will evaluate with Beery- Buktenica Developmental Test of Visual Motor Integration and Peabody. Parents are evaluated World Health Organization Quality of Life - BREF and State - Trait Anxiety Inventory.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regrese Group</arm_group_label>
    <description>Children with premature retinopathy haven't applied any invasive treatment method. All cases are evaluated with Snellen Test, Autorefractometer, Titmus Stereo Fly Test, Optical Kohlerans Tomography, Peabody Developmental Motor Scales - II. Investigation of Visual Motor Integration will evaluate with Beery- Buktenica Developmental Test of Visual Motor Integration and Peabody. Parents are evaluated World Health Organization Quality of Life - BREF and State - Trait Anxiety Inventory.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Snellen Test</intervention_name>
    <description>Visual acuity measurement</description>
    <arm_group_label>Anti-VEGF Group</arm_group_label>
    <arm_group_label>Laser Group</arm_group_label>
    <arm_group_label>Regrese Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Autorefractometer</intervention_name>
    <description>Refraction measurement</description>
    <arm_group_label>Anti-VEGF Group</arm_group_label>
    <arm_group_label>Laser Group</arm_group_label>
    <arm_group_label>Regrese Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Titmus Stereo Fly Test</intervention_name>
    <description>Stereopsis measurement</description>
    <arm_group_label>Anti-VEGF Group</arm_group_label>
    <arm_group_label>Laser Group</arm_group_label>
    <arm_group_label>Regrese Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Optical Kohlerans Tomography</intervention_name>
    <description>Retinal development measurement</description>
    <arm_group_label>Anti-VEGF Group</arm_group_label>
    <arm_group_label>Laser Group</arm_group_label>
    <arm_group_label>Regrese Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Investigation of Visual Motor Integration</intervention_name>
    <description>Investigation of visual motor integration, motor coordination and visual perception by Beery- Buktenica Developmental Test of Visual Motor Integration.</description>
    <arm_group_label>Anti-VEGF Group</arm_group_label>
    <arm_group_label>Laser Group</arm_group_label>
    <arm_group_label>Regrese Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Peabody Developmental Motor Scales - II</intervention_name>
    <description>Evaluation of motor development</description>
    <arm_group_label>Anti-VEGF Group</arm_group_label>
    <arm_group_label>Laser Group</arm_group_label>
    <arm_group_label>Regrese Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>World Health Organization Quality of Life - BREF</intervention_name>
    <description>Assesment of quality of life</description>
    <arm_group_label>Anti-VEGF Group</arm_group_label>
    <arm_group_label>Laser Group</arm_group_label>
    <arm_group_label>Regrese Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>State - Trait Anxiety Inventory</intervention_name>
    <description>Assesment of anxiety</description>
    <arm_group_label>Anti-VEGF Group</arm_group_label>
    <arm_group_label>Laser Group</arm_group_label>
    <arm_group_label>Regrese Group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participants who were followed up and treated in the outpatient clinic of Zeynep Kamil
        Women and Children Diseases Training and Research Hospital, Ophthalmology Clinic with the
        diagnosis of Prematurity Retinopathy between the years 2012-2015 were included in the
        study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age range between 2-6 years of age

          -  Gestational age range 26-34. be between weeks

          -  To be diagnosed with retinopathy of prematurity

          -  Neurological, hereditary and not having metabolic disease

          -  Compliance with visual examinations and physiotherapy evaluations

          -  To be children and parents who agree to participate in the study

        Exclusion Criteria:

          -  To be a child who does not comply with Optical Kohlerans Tomography (OCT)

          -  Not participating in one or more of the eye examination or physiotherapy assessments

          -  Being children and parents who do not agree to participate in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>6 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zeliha Candan Algun</last_name>
    <role>Study Director</role>
    <affiliation>Istanbul Medipol University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Istanbul Medipol University</name>
      <address>
        <city>Istanbul</city>
        <state>Beykoz</state>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Rothman AL, Mangalesh S, Chen X, Toth CA. Optical coherence tomography of the preterm eye: from retinopathy of prematurity to brain development. Eye Brain. 2016 May 27;8:123-133. doi: 10.2147/EB.S97660. eCollection 2016. Review.</citation>
    <PMID>28539807</PMID>
  </reference>
  <reference>
    <citation>Kabataş EU, Kurtul BE, Altıaylık Özer P, Kabataş N. Comparison of Intravitreal Bevacizumab, Intravitreal Ranibizumab and Laser Photocoagulation for Treatment of Type 1 Retinopathy of Prematurity in Turkish Preterm Children. Curr Eye Res. 2017 Jul;42(7):1054-1058. doi: 10.1080/02713683.2016.1264607. Epub 2017 Jan 27.</citation>
    <PMID>28128986</PMID>
  </reference>
  <results_reference>
    <citation>Araz-Ersan B, Kir N, Tuncer S, Aydinoglu-Candan O, Yildiz-Inec D, Akdogan B, Ekici B, Demirel A, Ozmen M. Preliminary anatomical and neurodevelopmental outcomes of intravitreal bevacizumab as adjunctive treatment for retinopathy of prematurity. Curr Eye Res. 2015 May;40(6):585-91. doi: 10.3109/02713683.2014.941070. Epub 2014 Jul 15.</citation>
    <PMID>25025864</PMID>
  </results_reference>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>March 1, 2019</study_first_submitted>
  <study_first_submitted_qc>March 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 6, 2019</study_first_posted>
  <last_update_submitted>March 13, 2020</last_update_submitted>
  <last_update_submitted_qc>March 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vision Disorders</mesh_term>
    <mesh_term>Vision, Low</mesh_term>
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Retinopathy of Prematurity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

